October 7, 2025 — Leads & Copy — Precision BioSciences, Inc. (Nasdaq: DTIL) has activated its first U.S. clinical trial site at Massachusetts General Hospital in Boston to evaluate PBGENE-HBV as part of the ELIMINATE-B Phase 1 clinical trial. The site is now recruiting patients.
According to Cindy Atwell, Chief Development and Business Officer at Precision BioSciences, chronic hepatitis B remains a pressing global health challenge. The company is thrilled to open recruitment at Massachusetts General Hospital and expects to provide further data updates on the ELIMINATE-B study in 2025.
The Phase 1 ELIMINATE-B study is designed to evaluate the safety and tolerability of PBGENE-HBV and define the optimal dose for patients with chronic hepatitis B.
For more information on the trial, visit clinicaltrials.gov using identifier NCT06680232.
PBGENE-HBV is Precision’s wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial designed to potentially cure chronic hepatitis B infection.
Hepatitis B is a leading cause of morbidity in the US and death globally, with no curative options currently available for patients. Current treatments do not eradicate HBV cccDNA and require lifelong administration.
The Phase 1 ELIMINATE-B study is currently enrolling HBeAg-negative chronic hepatitis B patients at sites in Moldova, Hong Kong, New Zealand, and the U.S. Precision expects to expand the study to clinical trial sites in the U.K.
Contact:
Cindy Atwell, Chief Development and Business Officer at Precision BioSciences
